Healthy Volunteers Clinical Trial
Official title:
Double Blind, Randomized, Placebo Controlled Clinical and Instrumental Evaluation of the Efficacy of Two Dietary Supplements Claiming Anti-aging Properties
Verified date | September 2023 |
Source | Seppic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study is aimed to assess the efficacy of two dietary supplements composed of a Wheat Polar Lipid Complex (WPLC) in reducing skin aging signs, in particular in improving firmness/elasticity, skin moisturization and skin surface properties.
Status | Completed |
Enrollment | 72 |
Est. completion date | July 1, 2022 |
Est. primary completion date | July 1, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 30 Years to 60 Years |
Eligibility | Inclusion criteria : - Healthy female subjects, - Caucasian ethnicity, - Age between 30 and 60 years old (extremes included), - Wrinkles related to chronological ageing (from mild to moderate), - Wrinkles related to photo-ageing (medium photo-ageing signs, dry and devitalized skin, asphyxia, pale and greyish skin, early ageing signs caused by a slowing in the cells activity), - Subjects with dry skin defined with corneometric index < 50 a.u., - Body mass index BMI between 19 and 30, - At least 10 menopause women per group, - Subjects who have not been recently involved in any other similar study (evaluation is performed case by case by the experimenter but at least 1 month must be elapsed between a previous study on food supplement), - Willingness not to use chemical products or treatments on hair and nails (such as hair colour, straightening, permanent nail polish) in the two weeks preceding T56 visit, - Willingness to not use during the study period products other than the test product, - Willingness to not vary the normal diet and daily routine (at the beginning of the study volunteers list their usual routine: sport activities, sleeping habits, etc. ), - Subjects under effective contraception (oral/not oral) if women of childbearing potential; not expected to be changed during the trial, - Subjects who have not sun exposure (both natural or artificial) for at least two months - Subjects who accept not to expose in intensive way to UV rays during the whole study duration, - Willingness not to use similar products that could interfere with the product to be tested, - Subject aware of the study procedures and having signed an informed consent form. Exclusion Criteria: - Subject does not meet the inclusion criteria, - Subject with known or suspected sensitization to one or more test formulation ingredients, - Any condition that the principal investigator deems inappropriate for participation, - Pregnant/breastfeeding female or who have planned a pregnancy during the study period, - Pharmacological treatments (topic or systemic) known to interfere with skin metabolism/physiology, - Lipid metabolism disorders (hypercholesterolemia, hyperlipidemia) and following treatment for theses disease, - Subjects under locally pharmacological treatment on the skin area monitored during the test, - Subjects under treatment with food supplements which could interfere with the functionality of the product under study, - Subjects which show skin alterations on the monitored area which could interfere with the functionality of the product under study, - Subjects who underwent to botox, hyaluronic acid, collagen injections or each type of facial surgery in the past 6 months, - Severe concurrent diseases, - Adult protected by the law (under guardianship, or hospitalized in a public or private institution, for a reason other than the research, or incarcerated), - Subject is unable to communicate or cooperate with the Investigator due to language problems, poor mental development, or impaired cerebral function, - Subjects resulting positive to Sars-Cov. 19 in the past 6 months/ during the study - Subjects not presenting a valid Greenpass. |
Country | Name | City | State |
---|---|---|---|
Italy | Complife Italia srl | Milano |
Lead Sponsor | Collaborator |
---|---|
Seppic |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Skin moisturization | Skin moisturization is measured by the Corneometer®, which analyze the dielectric constant and therefore the water content of the skin | Baseline | |
Primary | Skin moisturization | Skin moisturization is measured by the Corneometer®, which analyze the dielectric constant and therefore the water content of the skin | 14 days | |
Primary | Skin moisturization | Skin moisturization is measured by the Corneometer®, which analyze the dielectric constant and therefore the water content of the skin | 28 days | |
Primary | Skin moisturization | Skin moisturization is measured by the Corneometer®, which analyze the dielectric constant and therefore the water content of the skin | 56 days | |
Primary | Skin moisturization | Skin moisturization is measured by the Corneometer®, which analyze the dielectric constant and therefore the water content of the skin | 56 days post supplementation | |
Secondary | Skin elasticity | Skin elasticity measurement is based on the suction/elongation method and the subsequent release of the skin inside the opening of the instrument (Cutometer®) | Baseline | |
Secondary | Skin elasticity | Skin elasticity measurement is based on the suction/elongation method and the subsequent release of the skin inside the opening of the instrument (Cutometer®) | 14 days | |
Secondary | Skin elasticity | Skin elasticity measurement is based on the suction/elongation method and the subsequent release of the skin inside the opening of the instrument (Cutometer®) | 28 days | |
Secondary | Skin elasticity | Skin elasticity measurement is based on the suction/elongation method and the subsequent release of the skin inside the opening of the instrument (Cutometer®) | 56 days | |
Secondary | Skin elasticity | Skin elasticity measurement is based on the suction/elongation method and the subsequent release of the skin inside the opening of the instrument (Cutometer®) | 56 days post supplementation | |
Secondary | Transepidermal water loss | The water evaporating from the skin is measured using a probe (Tewameter®) that detect changes in water vapor density | Baseline | |
Secondary | Transepidermal water loss | The water evaporating from the skin is measured using a probe (Tewameter®) that detect changes in water vapor density | 14 days | |
Secondary | Transepidermal water loss | The water evaporating from the skin is measured using a probe (Tewameter®) that detect changes in water vapor density | 28 days | |
Secondary | Transepidermal water loss | The water evaporating from the skin is measured using a probe (Tewameter®) that detect changes in water vapor density | 56 days | |
Secondary | Transepidermal water loss | The water evaporating from the skin is measured using a probe (Tewameter®) that detect changes in water vapor density | 56 days post supplementation | |
Secondary | Skin roughness | Skin roughness (Rz parameter) is measured by Primos CR, a 3D scanner using fringe projection to measure skin surface properties | Baseline | |
Secondary | Skin roughness | Skin roughness (Rz parameter) is measured by Primos CR, a 3D scanner using fringe projection to measure skin surface properties | 14 days | |
Secondary | Skin roughness | Skin roughness (Rz parameter) is measured by Primos CR, a 3D scanner using fringe projection to measure skin surface properties | 28 days | |
Secondary | Skin roughness | Skin roughness (Rz parameter) is measured by Primos CR, a 3D scanner using fringe projection to measure skin surface properties | 56 days | |
Secondary | Skin roughness | Skin roughness (Rz parameter) is measured by Primos CR, a 3D scanner using fringe projection to measure skin surface properties | 56 days post supplementation | |
Secondary | Skin smoothness | Skin smoothness (Ra parameter) is measured by Primos CR, a 3D scanner using fringe projection to measure skin surface properties | Baseline | |
Secondary | Skin smoothness | Skin smoothness (Ra parameter) is measured by Primos CR, a 3D scanner using fringe projection to measure skin surface properties | 14 days | |
Secondary | Skin smoothness | Skin smoothness (Ra parameter) is measured by Primos CR, a 3D scanner using fringe projection to measure skin surface properties | 28 days | |
Secondary | Skin smoothness | Skin smoothness (Ra parameter) is measured by Primos CR, a 3D scanner using fringe projection to measure skin surface properties | 56 days | |
Secondary | Skin smoothness | Skin smoothness (Ra parameter) is measured by Primos CR, a 3D scanner using fringe projection to measure skin surface properties | 56 days post supplementation | |
Secondary | Wrinkle depth | Wrinkle depth (Sv parameter) is measured by Primos CR, a 3D scanner using fringe projection to measure skin surface properties | Baseline | |
Secondary | Wrinkle depth | Wrinkle depth (Sv parameter) is measured by Primos CR, a 3D scanner using fringe projection to measure skin surface properties | 14 days | |
Secondary | Wrinkle depth | Wrinkle depth (Sv parameter) is measured by Primos CR, a 3D scanner using fringe projection to measure skin surface properties | 28 days | |
Secondary | Wrinkle depth | Wrinkle depth (Sv parameter) is measured by Primos CR, a 3D scanner using fringe projection to measure skin surface properties | 56 days | |
Secondary | Wrinkle depth | Wrinkle depth (Sv parameter) is measured by Primos CR, a 3D scanner using fringe projection to measure skin surface properties | 56 days post supplementation | |
Secondary | Self-assessment of product efficacy | Questionnaire (20 questions with 4 possible answers : completely agree / agree / disagree / completely disagree) | 56 days | |
Secondary | Skin lipidic profile | Untargeted lipidomic analysis : Extraction of lipids from skin stripping and quantification by ultra-high performance liquid chromatography coupled to mass spectrometry (relative peak intensity) | Baseline | |
Secondary | Skin lipidic profile | Untargeted lipidomic analysis : Extraction of lipids from skin stripping and quantification by ultra-high performance liquid chromatography coupled to mass spectrometry (relative peak intensity) | 56 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |